about
Physician Decision Making in Selection of Second-Line Treatments in Immune Thrombocytopenia in Children.Fostamatinib for the Treatment of Adult Persistent and Chronic Immune Thrombocytopenia: Results of Two Phase 3, Randomized, Placebo-Controlled Trials.Combination of thrombopoietin receptor agonists, immunosuppressants and intravenous immunoglobulin as treatment of severe refractory immune thrombocytopenia in adults and childrenResponse to thrombopoietic agents is related to on-treatment bone marrow megakaryocyte morphology in patients with chronic immune thrombocytopeniaHealth-related quality of life in children with chronic immune thrombocytopenia treated with eltrombopag in the PETIT studyFetal and neonatal alloimmune thrombocytopenia: recommendations for evidence-based practice, an international approachLong-term sustained response to fostamatinib in two patients with chronic refractory immune thrombocytopenia (ITP)FAS mutations are an uncommon cause of immune thrombocytopenia in children and adults without additional features of immunodeficiencyFatigue in children and adolescents with immune thrombocytopenia
P50
Q52320502-AB38FE9C-C8D2-42CB-B21C-AAAA544225C6Q52562217-E52B65E9-779A-4A00-B5B9-EC0B18536103Q89872108-BA65777D-EFFA-4203-B4D8-EFE766777BE1Q90230554-0C67F287-2D1F-4450-ABBA-B48B3E37D7EDQ90787128-6C99B3FA-2DB6-4377-AF1F-95441F2A3E9BQ92091325-43A61006-A1C0-4FAB-816D-7E1ABD6FBAB1Q92411095-09DCD646-ECAA-41C9-967E-79D17FFCEAE7Q92576899-30A4DD96-DAF2-4451-AA03-FDFD688EA2FFQ96163397-68CF72DC-B593-4F7E-9BD0-DCC843EF8D36
P50
description
researcher
@en
name
James B Bussel
@en
type
label
James B Bussel
@en
prefLabel
James B Bussel
@en
P31
P496
0000-0002-2884-9247